期刊文献+

Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C 被引量:8

Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C
下载PDF
导出
摘要 AIM: To study predictive factors of thyroid dysfunction associated with interferon-alpha (IFNa) therapy in chronic hepatitis C (CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction. METHODS: We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNα from 1999 to 2004. RESULTS: Thyroid disorder developed in 30/301 (10%) patients with a mean delay of 6 ± 3.75 mo: 13 patients had hyperthyroidism, 11 had hypothyroidism, and 6 had biphasic evolution. During a mean follow-up of 41.59 ± 15.39 mo, 9 patients with hyperthyroidism, 3 with hypothyroidism, and 4 with biphasic evolution normalized thyroid function in 7.88 ± 5.46 mo. Recovery rate of dysthyroidism was not modified by treatment discontinuation, but was better for patients with negative thyroid antibodies before antiviral treatment (P = 0.02). Women had significantly more dysthyroidism (P = 0.05). Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism (P 〈 0.0003 and P = 0.0003, respectively). In a multivariate model, low fibrosis was found to be a predictive factor of dysthyroidism (P = 0.039).CONCLUSION: In this monocentric population of CHC, dysthyroidism, especially hyperthyroidism, developed in 10% of patients, Low fibrosis was found to be a predictive factor of dysthyroidism, Thyroid disorder recovered in 16/30 patients (53%) and recovery was better in the non-autoimrnune form, AIM:To study predictive factors of thyroid dysfunction associated with interferon-alpha(IFNα) therapy in chronic hepatitis C(CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction.METHODS:We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNα from 1999 to 2004.RESULTS:Thyroid disorder developed in 30/301(10%) patients with a mean delay of 6 ± 3.75 mo:13 patients had hyperthyroidism,11 had hypothyroidism,and 6 had biphasic evolution.During a mean follow-up of 41.59 ± 15.39 mo,9 patients with hyperthyroidism,3 with hypothyroidism,and 4 with biphasic evolution normalized thyroid function in 7.88 ± 5.46 mo.Recovery rate of dysthyroidism was not modified by treatment discontinuation,but was better for patients with negative thyroid antibodies before antiviral treatment(P = 0.02).Women had signif icantly more dysthyroidism(P = 0.05).Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism(P < 0.0003 and P = 0.0003,respectively).In a multivariate model,low fibrosis was found to be a predictive factor of dysthyroidism(P = 0.039).CONCLUSION:In this monocentric population of CHC,dysthyroidism,especially hyperthyroidism,developed in 10% of patients.Low fibrosis was found to be a predictive factor of dysthyroidism.Thyroid disorder recovered in 16/30 patients(53%) and recovery was better in the non-autoimmune form.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第3期328-333,共6页 世界胃肠病学杂志(英文版)
关键词 Chronic hepatitis C Interferon alpha Predictive factors Thyroid disorder 慢性丙肝 干扰素 甲状腺紊乱 治疗方法
  • 相关文献

参考文献22

  • 1Manns MP,McHutchison JG,Gordon SC,Rustgi VK,Shiffman M,Reindollar R,Goodman ZD,Koury K,Ling M,Albrecht JK.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet 2001; 358:958-965
  • 2Fried MW,Shiffman ML,Reddy KR,Smith C,Marinos G,Goncales FL Jr,Haussinger D,Diago M,Carosi G,Dhumeaux D,Craxi A,Lin A,Hoffman J,Yu J.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med 2002; 347:975-982
  • 3Consensus conference.Treatment of hepatitis C.Gastroenterol Clin Biol 2002; 26 Spec No 2:B303-B320
  • 4Preziati D,La Rosa L,Covini G,Marcelli R,Rescalli S,Persani L,Del Ninno E,Meroni PL,Colombo M,Beck-Peccoz P.Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.Eur J Endocrinol 1995; 132:587-593
  • 5Benelhadj S,Marcellin P,Castelnau C,Colas-Linhart N,Benhamou JP,Erlinger S,Bok B.Incidence of dysthyroidism during interferon therapy in chronic hepatitis C.Horm Res 1997; 48:209-214
  • 6Carella C,Mazziotti G,Morisco F,Manganella G,Rotondi M,Tuccillo C,Sorvillo F,Caporaso N,Amato G.Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment.J Clin Endocrinol Metab 2001; 86:1925-1929
  • 7Dalgard O,Bjoro K,Hellum K,Myrvang B,Bjoro T,Haug E,Bell H.Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha:no association with either interferon dosage or efficacy of therapy.J Intern Med 2002;251:400-406
  • 8Marazuela M,Garcia-Buey L,Gonzalez-Fernandez B,Garcia-Monzon C,Arranz A,Borque MJ,Moreno-Otero R.Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy.Clin Endocrinol (Oxf) 1996; 44:635-642
  • 9Mekkakia-Benhabib C,Marcellin P,Colas-Linhart N,Castel-Nau C,Buyck D,Erlinger S,Bok B.[Natural history of dysthyroidism during interferon treatment of chronic hepatitis C] Ann Endocrinol (Paris) 1996; 57:419-427
  • 10Roti E,Minelli R,Giuberti T,Marchelli S,Schianchi C,Gardini E,Salvi M,Fiaccadori F,Ugolotti G,Neri TM,Braverman LE.Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha.Am J Med 1996; 101:482-487

同被引文献21

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部